Market Place
Sourcing Support
Rocket Pharma Announces Upsized Public Offering Pricing
11 Dec 2024 //
BUSINESSWIRE
Rocket Pharmas Announces Proposed Public Offering of Common Stock
10 Dec 2024 //
BUSINESSWIRE
Children`s Hospital Announces Gene Therapy Results for Danon
18 Nov 2024 //
PR NEWSWIRE
Rocket Pharma to Present RP-A501 Data for Danon Disease at AHA 2024
12 Nov 2024 //
BUSINESSWIRE
Rocket Pharma at UBS Global Healthcare Conference
08 Nov 2024 //
BUSINESSWIRE
Rocket Pharma Q3 2024 Results & Recent Progress Highlights
07 Nov 2024 //
BUSINESSWIRE
Rocket Pharmaceuticals Completes Enrollment In Phase 2 Danon Disease Trial
17 Sep 2024 //
BUSINESSWIRE
Rocket Appoints Mikael Dolsten To Board Of Directors
10 Sep 2024 //
BUSINESSWIRE
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
27 Aug 2024 //
BUSINESSWIRE
Rocket Pharmaceuticals Reports Q2 2024 Results And Recent Progress
05 Aug 2024 //
BUSINESSWIRE
US FDA declines to approve Rocket Pharma`s immune disorder gene therapy
29 Jun 2024 //
REUTERS
Rocket Gene Therapy`s Approval Delayed By FDA Rejection Over Manufacture Issues
28 Jun 2024 //
FIERCE BIOTECH
EC grants orphan medicinal product status to Rocket’s RP-A601
30 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Rocket Gets EU Orphan Status For RP-A601 In PKP2 Cardiomyopathy
29 May 2024 //
BUSINESSWIRE
Rocket Pharma LV Hematology Portfolio Data At ASGCT 2024
10 May 2024 //
BUSINESSWIRE
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results
06 May 2024 //
BUSINESSWIRE
Rocket Pharma Announces EMA Acceptance of RP-L102 MAA for the Fanconi Anemia
02 Apr 2024 //
BUSINESSWIRE
Rocket Announces Appointment of Aaron Ondrey as CFO and Additional Updates
26 Mar 2024 //
BUSINESSWIRE
Rocket Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
BUSINESSWIRE
Rocket Pharma to light up buildings again for Rare Disease Day
26 Feb 2024 //
ENDPTS
Is Rocket Pharmaceuticals Inc Stock at the Top of the Biotechnology Industry?
13 Feb 2024 //
INVESTOR OBSERVER
FDA delays PDUFA date for Rocket’s rare white blood cell disorder gene therapy
13 Feb 2024 //
ENDPTS
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
12 Dec 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral
19 Oct 2023 //
BUSINESSWIRE
Rocket Announces FDA Acceptance of BLA with Priority Review for RP-L201
02 Oct 2023 //
BUSINESSWIRE
Rocket to Participate in the Chardan 7th Annual Genetic Medicines Conference
26 Sep 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
13 Sep 2023 //
BUSINESSWIRE
Rocket boosted by FDA alignment on pivotal gene therapy trial
13 Sep 2023 //
FIERCE BIOTECH
Rocket Pharma Reaches FDA Alignment on Pivotal Phase 2 Trial for RP-A501
12 Sep 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12 Sep 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
06 Sep 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Rocket Lab Spacecraft Built for Varda Successfully Operating on Orbit
12 Jun 2023 //
BUSINESSWIRE
US FDA grants Fast Track & Orphan Drug designations to Rocket Pharma’s RP-A601
10 Jun 2023 //
PHARMABIZ
Rocket Receives FDA Fast Track and Orphan Drug Designations for RP-A601
08 Jun 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Receives EMA Priority Medicines Designation for RP-A501
31 May 2023 //
BUSINESSWIRE
Rocket Receives FDA RMAT Designation for RP-L301
23 May 2023 //
BUSINESSWIRE
Rocket`s hematology programs blast off toward regulators
19 May 2023 //
FIERCE BIOTECH
Rocket Presents Data from LV Hematology & AAV Cardiovascular Programs
19 May 2023 //
BUSINESSWIRE
Rocket Pharma receives FDA IND clearance for ACM Phase I trial
10 May 2023 //
CLINICAL TRIALS ARENA
Rocket Pharmaceuticals Announces FDA Clearance of IND for Trial of RP-A601
09 May 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Reports 1Q 2023 FYR and Highlights Recent Progress
04 May 2023 //
BUSINESSWIRE
Rocket Pharma to Participate in the Bank of America Securities 2023 Conference
03 May 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
11 Apr 2023 //
BUSINESSWIRE
Rocket Announce Leadership Expansion to Support Company Towards Commercial Stage
04 Apr 2023 //
BUSINESSWIRE
Rocket Pharma to Participate in the 43rd Annual Cowen Health Care Conference
01 Mar 2023 //
BUSINESSWIRE
Rocket Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
BUSINESSWIRE
Rocket Pharma re-ups rare disease awareness with Empire State Building light-up
24 Feb 2023 //
ENDPTS
Rocket Pharma to Present at the SVB Securities Global Biopharma Conference
09 Feb 2023 //
BUSINESSWIRE
Rocket receives show of confidence in gene therapy from FDA
07 Feb 2023 //
FIERCE BIOTECH
Rocket Pharma Expands Cardiac Gene Therapy Portfolio for PKP2-ACM
09 Jan 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Rocket Pharma Provides Update on Anticipated Registration Path for RP-A501
22 Dec 2022 //
PRESS RELEASE
Rocket Pharmaceuticals Presents Positive Data from Fanconi Anemia at ASH
12 Dec 2022 //
BUSINESSWIRE
Rocket Pharmaceuticals Completes Acquisition of Renovacor
01 Dec 2022 //
BUSINESSWIRE
Rocket Pharma to Present at the 5th Annual Evercore ISI HealthCONx Conference
21 Nov 2022 //
BUSINESSWIRE
Rocket Announces Presentations Highlighting AAV and Lentiviral Gene Therapies
03 Nov 2022 //
BUSINESSWIRE
Rocket Pharma Reports Q3 2022 Financial Results and Highlights Recent Progress
03 Nov 2022 //
BUSINESSWIRE
Rocket PharmaAnnounces Presentations Highlighting Lentiviral Gene Therapies
12 Oct 2022 //
BUSINESSWIRE
